Search

Your search keyword '"Dunning A.M."' showing total 206 results
Start Over Author "Dunning A.M."
206 results on '"Dunning A.M."'

202. Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions

Author

Manuguerra, M., primary, Matullo, G., additional, Veglia, F., additional, Autrup, H., additional, Dunning, A.M., additional, Garte, S., additional, Gormally, E., additional, Malaveille, C., additional, Guarrera, S., additional, Polidoro, S., additional, Saletta, F., additional, Peluso, M., additional, Airoldi, L., additional, Overvad, K., additional, Raaschou-Nielsen, O., additional, Clavel-Chapelon, F., additional, Linseisen, J., additional, Boeing, H., additional, Trichopoulos, D., additional, Kalandidi, A., additional, Palli, D., additional, Krogh, V., additional, Tumino, R., additional, Panico, S., additional, Bueno-De-Mesquita, H.B., additional, Peeters, P.H., additional, Lund, E., additional, Pera, G., additional, Martinez, C., additional, Amiano, P., additional, Barricarte, A., additional, Tormo, M.J., additional, Quiros, J.R., additional, Berglund, G., additional, Janzon, L., additional, Jarvholm, B., additional, Day, N.E., additional, Allen, N.E., additional, Saracci, R., additional, Kaaks, R., additional, Ferrari, P., additional, Riboli, E., additional, and Vineis, P., additional

Published
2006
Full Text
View/download PDF

203. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study

Author

Matullo, G., primary, Dunning, A.M., additional, Guarrera, S., additional, Baynes, C., additional, Polidoro, S., additional, Garte, S., additional, Autrup, H., additional, Malaveille, C., additional, Peluso, M., additional, Airoldi, L., additional, Veglia, F., additional, Gormally, E., additional, Hoek, G., additional, Krzyzanowski, M., additional, Overvad, K., additional, Raaschou-Nielsen, O., additional, Clavel-Chapelon, F., additional, Linseisen, J., additional, Boeing, H., additional, Trichopoulou, A., additional, Palli, D., additional, Krogh, V., additional, Tumino, R., additional, Panico, S., additional, Bueno-De-Mesquita, H.B., additional, Peeters, P.H., additional, Lund, E., additional, Pera, G., additional, Martinez, C., additional, Dorronsoro, M., additional, Barricarte, A., additional, Tormo, M.J., additional, Quiros, J.R., additional, Day, N.E., additional, Key, T.J., additional, Saracci, R., additional, Kaaks, R., additional, Riboli, E., additional, and Vineis, P., additional

Published
2005
Full Text
View/download PDF

204. Identification of a C/G polymorphism in the promoter region of the BRCA1 gene and its use as a marker for rapid detection of promoter deletions.

Author

Catteau, A., Xu, C.-F., Brown, M.A., Hodgson, S., Greenman, J., Mathew, C.G., Dunning, A.M., and Solomon, E.

Subjects
BREAST cancer, CANCER treatment, MEDICAL screening, MEDICAL research
Abstract

Reduced expression of BRCA1has been implicated in sporadic breast cancer, although the mechanisms underlying this phenomenon remain unclear. To determine whether regulatory mutations could account for the reduced expression, we screened the promoter region by sequencing in 20 patients with sporadic disease. No mutations were detected; however, a new polymorphism consisting of a C-to-G base change within the β-promoter was identified, with the frequency of the G allele being 0.34. Close to complete linkage disequilibrium was found between this marker and the Pro871Leu polymorphism, situated in exon 11, which has previously been shown not to be associated with breast or ovarian cancer. This indicates that the C/G polymorphism is also unlikely to play a role in either disease. However, the strength of linkage disequilibrium between these markers permitted their use for rapid screening for genomic deletions within BRCA1. A series of 214 cases with familial breast cancer were analysed using this approach; 88/214 were heterozygous for the promoter polymorphism, thereby excluding a deletion in this region. Among the remaining patients, one hemizygous case reflecting a promoter deletion was successfully identified. Therefore, this study indicates that deletions within the β-promoter region of BRCA1are an uncommon event in familial breast cancer. Furthermore, it suggests that mutations within the BRCA1promoter are unlikely to account for the reported decreased expression of BRCA1in sporadic disease. 1999 Cancer Research Campaign [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

205. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer

Author

Luben, R.N., Easton, D.F., Durocher, F., Dunning, A.M., McBride, S., Gregory, J., Foster, N.A., Healey, C.S., Smith, N., Pharoah, P.D.P., and Ponder, B.A.J.

Abstract

Endogenous hormone exposure is known to alter breast cancer susceptibility and genes responsive to such hormones are plausible candidates for predisposition genes. We have examined polymorphisms in genes for two members of the nuclear receptor superfamily which are expressed in breast tissue and known to moderate rates of cell proliferation in a case-control association study: the androgen receptor (AR) and the vitamin D receptor (VDR). We have used two series of Caucasian female breast cancer cases, one incident and one prevalent, and compared both with two sets of matched controls from the East Anglian region of Britain. Since the results are similar in the two series we have combined them. The AR poly[Gly]n and poly[Gln]n tracts were genotyped in a total of 508 female breast cancer cases and 426 controls. The VDR TaqI polymorphism was analysed in 951 cases and 627 controls drawn from the same population series. There were no significant differences between cases and controls for either the AR or VDR polymorphisms. Compared with individuals with two short alleles (<22 repeats) of the AR poly[Gln]n tract, the odds ratios and 95% confidence intervals (95% CI) for individuals with one or two long alleles were 0.82 (95% CI 0.62-1.09) and 1.31 (95% CI 0.87-1.97), respectively. Heterozygotes and homozygotes for the VDR TaqI cutting site had odds ratios of 1.01 (95% CI 0.81-1.27) and 0.97 (95% CI 0.71-1.32), respectively. None of the AR or VDR polymorphisms investigated has a major effect on risk of breast cancer in the British population.

Published
1999

206. 5 Young Investigator Awardee - Predictors of long-term adverse quality of life following breast cancer treatment – Insights from the REQUITE cohort study.

Author

Jandu, H., Veal, C., Seibold, P., Azria, D., Chang-Claude, J., Choudhury, A., Dunning, A.M., De Ruysscher, D., Gutierrez-Enriquez, S., Rancati, T., Rosenstein, B.S., Sperk, E., Stobart, H., Symonds, R.P., Talbot, C.J., Valdagni, R., Vega, A., Veldeman, L., Webb, A.J., and West, C.

Subjects
*BREAST tumor treatment, *CONFERENCES & conventions, *QUALITY of life
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results